Mutational landscape of pancreatic NETs – Using the “liquid biopsy” to study genetic evolution over time and through therapy

Year: 2017
Institution: Memorial Sloan Kettering Cancer Center (MSK)
Country: United States
State: NY
Award Type: Pilot
NET Type: Pancreas
Science Type: Clinical

Description

Annes and his team will work to validate well-tolerated chemotherapeutic drugs that are selectively activated by and toxic toward NETs. This NET-Smart strategy is a pioneering platform technology applicable to numerous chemotherapeutics that may ultimately transform the treatment of NETs.

What question will the researchers try to answer?

Although medications are available that can eradicate any and all cancer cells in a dish, these same medications are only partially effective in people. The main reason for this discrepancy is that the amount and duration of chemotherapy treatment needed to kill all the cancer cells is too toxic toward healthy cells. In other words, the problem with these treatments is not that they couldn’t work; the problem is that doctors don’t have a way to specifically target the cancer cells. This challenge is particularly acute for the treatment for neuroendocrine cancers, which generally grow slower than several normal tissues such as the blood system and gastrointestinal tract. The use of highly effective cell-killing chemotherapeutic treatments, which depend upon cellular growth to work, is therefore prevented by hematologic and gastrointestinal side-effects. In this project, Dr. Annes and his team are asking whether it is possible to modify highly toxic chemotherapies so that they selectively target neuroendocrine cancer cells.

Why is this important?

Patients are in need a curative treatment for neuroendocrine cancer!

What will researchers do?

In their preliminary work, which was conducted with support of NETRF, Dr. Annes and his team devised a strategy to selectively target highly toxic drugs specifically to neuroendocrine cancer cells. In this project, they will build upon their initial success to improve the medications they  have developed and to test whether they work in mouse models of neuroendocrine cancers.

How might this improve the treatment of NETs?

The goal of this project is to develop cytotoxic medications that are well-tolerated (little to no side effects) so they can be used at sufficient doses to cure neuroendocrine cancers.

What is the next step?

Dr. Annes and his team aim to improve upon the drugs they have developed and prove that they work in mice with neuroendocrine cancers. Their goal is to show that our drugs can kill the tumors in mice without causing side effects. If this works, the research team will then develop additional preclinical safety data and prepare to test their medications in people. Because they are starting with medications that are already used in humans, the team anticipates that their road to human trials will be accelerated.